James D. Doecke

Oct 30, 2024 | onlinelibrary.wiley.com | Pratishtha Chatterjee |James D. Doecke |Nicholas Ashton |Tahmida Sharmin

1 INTRODUCTION Given a multifactorial disorder, Alzheimer's disease (AD) pathogenesis involves dysregulation in diverse biochemical processes (Dorszewska et al., 2016; Koutsodendris et al., 2022; López-Ortiz et al., 2021), including abnormal amyloid-β (Aβ) production and impaired Aβ clearance, tau hyperphosphorylation, insufficiency in brain glucose utilisation, mitochondrial dysfunction, lipid dyshomeostasis, oxidative stress, neuroinflammation and neurotransmitter dyshomeostasis (Toledo et...

Sep 11, 2024 | nature.com | Xin Huang |Yijun Pan |Céline Dubois |Holly Chinnery |James D. Doecke |Yong Lin | +1 more

AbstractImpaired clearance of amyloid β (Aβ) in late-onset Alzheimer’s disease (AD) affects disease progression. The role of peripheral monocytes in Aβ clearance from the central nervous system (CNS) is unclear. We use a flow cytometry assay to identify Aβ-binding monocytes in blood, validated by confocal microscopy, Western blotting, and mass spectrometry. Flow cytometry immunophenotyping and correlation with AD biomarkers are studied in 150 participants from the AIBL study.